Skip to main content
AVANOS MEDICAL, INC. logo

AVANOS MEDICAL, INC. — Investor Relations & Filings

Ticker · AVNS ISIN · US40650V1008 LEI · 549300YCXWOM7NEWMQ58 US Manufacturing
Open in API
Filings indexed 673 across all filing types
Latest filing 2022-07-22 Director's Dealing
Country US United States of America
Listing US AVNS

About AVANOS MEDICAL, INC.

https://avanos.com/

Avanos Medical, Inc. is a medical technology company that develops, manufactures, and markets medical device solutions. The company's portfolio is focused on two primary segments: Pain Management & Recovery and Enteral Feeding. The Pain Management & Recovery division provides a range of non-opioid therapies and solutions for managing chronic and post-surgical pain, targeting specialties such as anesthesiology, orthopedics, and interventional pain management. The Enteral Feeding division offers a comprehensive portfolio of nutrition delivery systems and products for a wide spectrum of patients, from neonates and pediatrics to adults, supporting healthcare providers in critical and long-term care settings. The company is focused on delivering clinically superior solutions that improve patient outcomes and facilitate recovery.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2022-07-22 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details the entry into a new Credit Agreement, termination of a prior credit agreement, and creation of a direct financial obligation. It focuses on financing activities, including loan terms, credit facilities, and covenants. There are no financial statements or comprehensive financial performance data presented, so it is not an Annual Report (10-K) or Interim Report (IR). The document is not a simple announcement of a report publication but a substantive update on financing. Therefore, it fits best under Capital/Financing Update (CAP). The document length (8705 characters) supports it being a full report rather than a brief announcement. Hence, the classification is CAP with high confidence.
2022-06-30 English
FORM SD
Regulatory Filings Classification · 95% confidence The document is a Form SD filed with the SEC, specifically a Specialized Disclosure Report related to conflict minerals for the year ended December 31, 2021. It references the Conflict Minerals Report as an exhibit and provides details about the due diligence process on the source of minerals. The document is regulatory in nature, focused on compliance with SEC rules regarding conflict minerals disclosure. It does not contain full financial statements or detailed financial performance data, nor is it an announcement of a report publication. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance filings that do not fit other specific categories.
2022-06-16 English
FORM 4
Director's Dealing
2022-06-10 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content specifically details the departure and retirement plans of a senior executive, including retention incentives and equity vesting arrangements. This fits the description of announcements related to changes in the company's board of directors or senior management. The document is not a full financial report, earnings release, or other types of filings. Therefore, it should be classified as Board/Management Information (MANG). The document length and detail support a confident classification.
2022-05-25 English
FORM 8-K
Transaction in Own Shares Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated May 16, 2022, by Avanos Medical, Inc. The content describes the approval of a new one-year share repurchase program allowing the company to buy back up to $25 million of its common stock. It details the terms and conditions of the repurchase program but does not contain financial statements or detailed financial analysis. The document is short (3658 characters) and focuses on announcing a share repurchase program, which aligns with a Transaction in Own Shares filing rather than a full financial report or other categories. Therefore, the appropriate classification is POS (Transaction in Own Shares).
2022-05-17 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.